1.
Davie A, TraorĂ© S, Giovannitti M, Pompilio G, Lambton M, Cakar E, Chatterjee A. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy. Grhta [Internet]. 2023 Sep. 28 [cited 2024 Nov. 23];10(1):62-9. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2561